Initial Statement of Beneficial Ownership (3)
May 05 2020 - 5:18PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Gullotta Tina |
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/28/2020
|
3. Issuer Name and Ticker or Trading Symbol
SUNESIS PHARMACEUTICALS INC [SNSS]
|
|
(Last)
(First)
(Middle)
SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
VP, Finance / |
|
(Street)
SOUTH SAN FRANCISCO, CA 94080
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Common Stock | 14500 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | (1) | 8/31/2028 | Common Stock | 40000 | $2.18 | D | |
| Stock Option (Right to Buy) | (2) | 12/31/2028 | Common Stock | 8611 | $0.4157 | D | |
| Stock Option (Right to Buy) | (3) | 3/29/2029 | Common Stock | 10000 | $1.215 | D | |
| Stock Option (Right to Buy) | (4) | 3/31/2030 | Common Stock | 70000 | $0.4149 | D | |
| Explanation of Responses: |
| (1) | One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of August 31, 2018. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months. |
| (2) | One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of December 31, 2018. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months. |
| (3) | One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 29, 2019. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months. |
| (4) | One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 31, 2020. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Gullotta Tina
SUNESIS PHARMACEUTICALS, INC.
395 OYSTER POINT BOULEVARD, SUITE 400
SOUTH SAN FRANCISCO, CA 94080 |
|
| VP, Finance |
|
Signatures
|
| /s/ Tina Gullotta | | 5/5/2020 |
| **Signature of Reporting Person | Date |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2023 to Apr 2024
